

# Supporting Information

Meng et al. 10.1073/pnas.0913759107

## SI Materials and Methods

**Expression Analysis.** One microgram total RNA, isolated using TRIzol reagent (Invitrogen) and purified with DNase treatment (Promega), was reverse transcribed into cDNA with random primers using M-MLV reverse transcriptase (Promega) in a 25- $\mu$ L volume. cDNA (0.5  $\mu$ L) or total RNA (0.5  $\mu$ g) (no RT as DNA contamination control) was used directly as PCR template. DNA Engine Opticon 1 (MJ Research) was used for real-time quantitative PCR with 18S rRNA as internal control. Relative quantitative PCR results were analyzed using the  $2^{-\Delta\Delta C_T}$  method (1).

**Screen for T-DNA Insertion Mutants.** Primers from the T-DNA left border LB1 and gene-specific primers (Table S2) were used to screen for the T-DNA insertion with PCR; results were confirmed by sequencing. Homozygous mutants for the T-DNA insertion were analyzed using RT-PCR. For the *Trx h9* mutant screen, 22% of the  $T_3$  plants in the Salk\_08660 line were heterozygous for the T-DNA insertion. No plants homozygous for the T-DNA insertion were found among  $T_3$  plants; 2.83% of the  $T_4$  progeny from two  $T_3$  heterozygous parental plants of Salk\_08660 line were found to be homozygous for the T-DNA insertion and for the null loss-of-function mutants of *Trx h9*. In the *Trx p* mutation screen, 28.6% of the  $T_3$  plants in Salk\_028162 were heterozygous for the T-DNA insertion; no homozygous T-DNA insertion plants were found among the  $T_3$  plants; 3.7% of  $T_4$  progeny from a  $T_3$  heterozygous parental plant of Salk\_028162 appeared to be as homozygous and null knockout mutants of *Trx p*. The non-Mendelian segregation ratios (ca 3% vs. 25%) for both the *trx h9* and *trx p* mutants suggest that the mutations in both cases have remarkably lowered the viability and passing of the inactive allele from parents to offspring.

**Transmission Electron Microscopy.** Transmission electron microscopy images were obtained following the protocols indicated for use of an FEI Tecnai 12 120-kV transmission electron microscope (<http://em-lab.berkeley.edu/EML/protocols.php>).

**Chlorophyll Analysis.** HPLC analysis of chlorophylls was done as described (2).

**Protein Extraction and Western Blot Analysis.** Soluble proteins were extracted from 7-day-old homozygous  $T_2$  transgenic *Arabidopsis* seedlings (3). Insoluble proteins present in the pellet were re-extracted with a buffer (50 mM Tris-HCl, 1.0% SDS, 2%  $\beta$ -mercaptoethanol, pH 8.0) by shaking at room temperature for 1 h. The western blot analysis of Trx-GFP was performed with a GFP antibody (Santa Cruz Biotechnology) as described (3).

**Trx *h9* May Dock via Interaction of N-Terminal Cys<sup>4</sup> with Catalytic Cys<sup>57</sup>.** Using PtTrx *h4* and other close homologs as templates for comparative modeling, we determined a predicted 3D structure for Trx *h9*. Unfortunately, amino acids 1–23, representing the

entire N-terminal extension of PtTrx*h4*, could not be located in the 3D structure due to the weak electron density of signals from this region (4). In view of this structural incompleteness, we proceeded to model Trx *h9* by applying I-TASSER simulation. With this approach, the missing portions of Trx *h9* were predicted, leading to a statistically reliable complete 3D structural model. C scores (from –5.0 to 2.0) and TM scores (from 0.0 and 1.0) measure the quality of a predicted model. C scores and TM scores for the models are, respectively, 0.03 and 0.72 for Trx *h9*; 0.03 and 0.69 for Trx *h9G2A*; –0.3 and 0.68 for Trx *h9C4W*; and –0.11 and 0.70 for Trx *h9C4S*. Each model was above the cutoff, that is, C score = –1.5, TM score = 0.5, and thus statistically valid (5).

**Docking Modeling of Trx*h9* Using a Two-Step Procedure of PatchDock and FireDock Services.** To explore docking properties of Trx *h9* with NTR and Grx, we predicted interaction models of Trx *h9* and AtNTRB (PDB ID code 1vdc), and of Trx *h9* and Grx. Two Grxs from poplar, PtGrxC1 (PDB ID code 1z7p) and PtGrxS12 (PDB ID code 3fz9), were used. A two-step procedure was used to study the docking models, starting with rigid-body docking by the PatchDock web server (6). These results were redirected for refinement and scoring by the FireDock server (7).

## SI Results and Discussion


**Grx, Not NTR, Fits in the Potential Binding Pocket of Trx *h9*.** Computational docking analysis of Trx *h9* revealed that Trx *h9* seemed not to interact with NADP-thioredoxin reductase (NTR), like other *h*-type Trxs (Fig. S6A vs. B). Rather, its predicted structure indicated that it was preferentially reduced by the GSH/Grx system, as for the poplar ortholog of Trx *h9*, PtTrx*h4* (8). NTR (AtNTRB) was too large to fit the Trx *h9* binding pocket, which did, however, accommodate PtGrxC1 (Fig. S6D and E). Specifically, the N-terminal arm of Trx *h9* appeared to interfere with NTR (AtNTRB) (Fig. S6A), but wrapped around Grx (PtGrxC1), yielding a tight and stable complex (Fig. S6D and E). Predicted specificity of Trx *h9* was supported by the observation that Trx *h1*, which is reduced by NTR (9), fits perfectly with the enzyme (AtNTRB) (Fig. S6B) but not with Grx (PtGrxC1) (Fig. S6B vs. C).

In contrast to its interference with binding Trx *h9* to the plasma membrane (Fig. 3E–H), mutation of Gly<sup>2</sup>, that is, Trx *h9G2A*, had no effect on the predicted interaction of Trx *h9* with Grx (PtGrxC1) (Fig. S6F and G). However, mutation of Cys<sup>4</sup> to tryptophan (Trx *h9C4W*) seemingly abolished this ability (Fig. S6H and I). Although the main body of the tryptophan mutant Trx *h9C4W* could interact with PtGrxC1, the N-terminal extension could not wrap around the partner molecule. A similar effect was seen when Cys<sup>4</sup> was mutated to Ser. When PtGrxS12 was used for docking, a similar result was obtained. The structures suggest that Trx *h9* links the Grx and Trx systems in redox signaling in *Ara-bidopsis*, as reported for poplar (4).


1. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta C(T)}$  method. *Methods* 25:402–408.
2. Müller-Moulé P, Conklin PL, Niyogi KK (2002) Ascorbate deficiency can limit violaxanthin de-epoxidase activity in vivo. *Plant Physiol* 128:970–977.
3. Cho M-J, et al. (1999) Overexpression of thioredoxin *h* leads to enhanced activity of starch debranching enzyme (pullulanase) in barley grain. *Proc Natl Acad Sci USA* 96: 14641–14646.
4. Koh CS, et al. (2008) An atypical catalytic mechanism involving three cysteines of thioredoxin. *J Biol Chem* 283:23062–23072.
5. Zhang Y (2008) I-TASSER server for protein 3D structure prediction. *BMC Bioinformatics* 9:40.

6. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ (2005) PatchDock and SymmDock: Servers for rigid and symmetric docking. *Nucleic Acids Res* 33 (Web Server issue):W363–W367.
7. Mashiah E, Schneidman-Duhovny D, Andrusier N, Nussinov R, Wolfson HJ (2008) FireDock: A web server for fast interaction refinement in molecular docking. *Nucleic Acids Res* 36 (Web Server issue):229–232.
8. Gelhaye E, Rouhier N, Jacquot JP (2003) Evidence for a subgroup of thioredoxin *h* that requires GSH/Grx for its reduction. *FEBS Lett* 555:443–448.
9. Meyer Y, Buchanan BB, Vignols F, Reichheld JP (2009) Thioredoxins and glutaredoxins: Unifying elements in redox biology. *Annu Rev Genet* 43:335–367.
10. Brown DP, Krishnamurthy N, Sjölander K (2007) Automated protein subfamily identification and classification. *PLoS Comput Biol* 3:e160.






**Fig. S2.** Protein sequence, gene expression and structure, and loss-of-function analysis of *Trx h9*. (A) Protein multiple-sequence alignment of *Trx h9* and its homologs using ClustalW2. (B) Tissue-specific expression of *Trx h9* in *Arabidopsis Col-0* plants retrieved from gene expression microarray data through the *Arabidopsis* eFP Browser (<http://www.bar.utoronto.ca/efp/cgi-bin/efpWeb.cgi>). Intensity of expression of *Trx h9* is indicated by the color scheme on the right. (C) RT-PCR analysis of *Trx h9* expression in different tissues of wild-type *Arabidopsis Col-0* plants. (D) Schematic representation of *Trx h9* structure with T-DNA insertion in Salk\_08660 line. (E) RT-PCR analysis of *Trx h9* expression in Salk\_08660 line: No RT as DNA contamination control. Internal control (bottom panel) used primers for 18S RNA. GenBank accession nos. in A: NP\_190672 (*Trx h1*), NP\_198811 (*Trx h2*), NP\_187483 (*Trx h9*), XP\_002309192 (PtTrx*h4*; *Populus trichocarpa*), AAD49233 [thioredoxin-like protein (*Phalaris coerulea*)], AAN63616 [thioredoxin *h*-like protein (*Hordeum vulgare* subsp. *vulgare*)], AAN63622 [thioredoxin (*Triticum aestivum*)], NP\_001042127 [Os01g0168200, *Trx* family protein (*Oryza sativa*)]. The classic catalytic site (WCGPC) of Trxs and the N-terminal extensions of *Trx h9* and its orthologs are indicated by rectangles in A. Asterisks denote conserved glycine and cysteine residues at positions 2 and 4, respectively, of the N-terminal extension of *Trx h9* in A.




**Fig. S3.** Phenotypic analysis of *trx h9* mutation in Salk\_08660 plants grown in light. (A) Ten-day-old *trx h9* mutant seedlings grown on MS medium without sucrose, showing absence of leaves. (B) The root tips of 7-day-old *Arabidopsis* seedlings grown on MS medium plus 1.0% sucrose (left to right: wild-type *Arabidopsis Col-0* plant, homozygous *trx h9* mutant, and 35S::Trx *h9* in *trx h9* background). (C) Eight-week-old *Arabidopsis* plants grown in soil (left to right: wild-type *Arabidopsis Col-0* plant, 35S::Trx *h9* in *trx h9* background, and homozygous *trx h9* mutant). [Scale bars, 1 cm (A), 50  $\mu$ m (B), 2 cm (C).]



## Transient expression in onion epidermis



**Fig. S4.** Confirmation of GFP fusions using transient expression in onion epidermal cells. (A–C) GFP only. (D) NLS-GFP. (A, D) Nonplasmolyzed, transformed onion epidermal cells. (B, C) Plasmolyzed, transformed onion epidermal cells. GFP visualized in B; DAPI staining visualized in C. (Scale bars, 10  $\mu$ m.)



**Fig. S5.** Western blot analysis of Trx-GFP fusion proteins using a GFP antibody. S and I represent the soluble and insoluble protein portions, respectively. M, SeeBlue Plus2 prestained standards (Invitrogen).

